Quantitative Investment Management LLC Takes $529,000 Position in Ascendis Pharma A/S $ASND

Quantitative Investment Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 1,985 shares of the biotechnology company’s stock, valued at approximately $529,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Advisory Services Network LLC acquired a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $26,000. Arax Advisory Partners grew its position in shares of Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after buying an additional 104 shares during the period. Leonteq Securities AG bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $42,000. Finally, Global Retirement Partners LLC boosted its stake in Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 113 shares during the last quarter.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime bought 2,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares in the company, valued at approximately $714,357. The trade was a 222.22% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Trading Down 1.1%

Shares of NASDAQ ASND opened at $260.25 on Wednesday. The company’s fifty day moving average is $256.87 and its 200-day moving average is $239.75. The stock has a market cap of $16.23 billion, a price-to-earnings ratio of 20.19 and a beta of 0.35. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. Equities research analysts predict that Ascendis Pharma A/S will post 3.9 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on ASND shares. Wedbush reaffirmed an “outperform” rating and set a $327.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday. Citigroup assumed coverage on Ascendis Pharma A/S in a research report on Monday, May 18th. They issued a “buy” rating and a $355.00 price target on the stock. TD Cowen lifted their price objective on Ascendis Pharma A/S from $325.00 to $341.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. UBS Group set a $345.00 price objective on Ascendis Pharma A/S in a research note on Monday. Finally, Oppenheimer reissued an “outperform” rating and issued a $312.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average target price of $310.05.

More Ascendis Pharma A/S News

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: BioMarin settlement removes litigation overhang: Ascendis and BioMarin entered a binding term sheet for a global settlement and license agreement covering YUVIWEL® and navepegritide-related products. The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty around the product. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL Shares increased following news of the license deal. Ascendis Pharma Shares Rise 6% Over License Deal With BioMarin Pharmaceutical
• Positive Sentiment: Wedbush remains bullish: Wedbush reaffirmed its “Outperform” rating and set a $327 price target, implying substantial upside from the referenced share price. The rating signals continued confidence in Ascendis’ growth prospects and product pipeline. Wedbush Reaffirms Ascendis Pharma Outperform Rating
• Neutral Sentiment: Analyst consensus remains favorable: Ascendis Pharma received an average analyst rating of “Buy,” indicating that Wall Street sentiment remains broadly positive despite recent estimate revisions. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Negative Sentiment: HC Wainwright cuts forward EPS forecasts: The firm reduced its estimates for the third and fourth quarters of 2026, all four quarters of 2027, and FY2027 EPS to $11.25 from $11.88. Although HC Wainwright maintained its “Buy” rating and $345 price target, the lower forecasts suggest a more cautious outlook for near-term earnings growth.
• Negative Sentiment: Bank of America trims its target: Bank of America lowered its price objective to $304 from $306 while retaining a “Buy” rating, representing a modest reduction in expected upside.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.